Loading...

Medicrea

ENXTPA:ALMED
Snowflake Description

Adequate balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
ALMED
ENXTPA
€45M
Market Cap
  1. Home
  2. FR
  3. Healthcare
Company description

Medicrea designs, manufactures, and distributes implants in France. The last earnings update was 227 days ago. More info.


Add to Portfolio Compare Print Invest
ALMED Share Price and Events
Price Volatility
ALMED
Industry
5yr Volatility vs Market

ALMED Value

 Is Medicrea undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Medicrea. This is due to cash flow or dividend data being unavailable. The share price is €2.68.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Medicrea's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Medicrea's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
ENXTPA:ALMED PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2017-12-31) in EUR €-0.93
ENXTPA:ALMED Share Price ** ENXTPA (2018-08-15) in EUR €2.68
France Medical Equipment Industry PE Ratio Median Figure of 5 Publicly-Listed Medical Equipment Companies 35.54x
France Market PE Ratio Median Figure of 430 Publicly-Listed Companies 17.49x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Medicrea.

ENXTPA:ALMED PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ENXTPA:ALMED Share Price ÷ EPS (both in EUR)

= 2.68 ÷ -0.93

-2.88x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Medicrea is loss making, we can't compare its value to the FR Medical Equipment industry average.
  • Medicrea is loss making, we can't compare the value of its earnings to the France market.
Price based on expected Growth
Does Medicrea's expected growth come at a high price?
Raw Data
ENXTPA:ALMED PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -2.88x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Europe Medical Equipment Industry PEG Ratio Median Figure of 162 Publicly-Listed Medical Equipment Companies 3.06x
France Market PEG Ratio Median Figure of 291 Publicly-Listed Companies 1.76x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Medicrea, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Medicrea's assets?
Raw Data
ENXTPA:ALMED PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2017-12-31) in EUR €1.45
ENXTPA:ALMED Share Price * ENXTPA (2018-08-15) in EUR €2.68
France Medical Equipment Industry PB Ratio Median Figure of 29 Publicly-Listed Medical Equipment Companies 2.13x
France Market PB Ratio Median Figure of 630 Publicly-Listed Companies 1.77x
ENXTPA:ALMED PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ENXTPA:ALMED Share Price ÷ Book Value per Share (both in EUR)

= 2.68 ÷ 1.45

1.85x

* Primary Listing of Medicrea.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Medicrea is good value based on assets compared to the FR Medical Equipment industry average.
X
Value checks
We assess Medicrea's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check)
  5. Medicrea has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

ALMED Future Performance

 How is Medicrea expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Medicrea has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

  • No analysts cover Medicrea, future earnings growth has been estimated based on fundamentals.
The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
9.6%
Expected Medical Equipment industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Medicrea expected to grow at an attractive rate?
  • Unable to compare Medicrea's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Medicrea's earnings growth to the France market average as no estimate data is available.
  • Unable to compare Medicrea's revenue growth to the France market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
ENXTPA:ALMED Future Growth Rates Data Sources
Data Point Source Value (per year)
France Medical Equipment Industry Earnings Growth Rate Market Cap Weighted Average 9.6%
France Medical Equipment Industry Revenue Growth Rate Market Cap Weighted Average 7.3%
France Market Earnings Growth Rate Market Cap Weighted Average 11.2%
France Market Revenue Growth Rate Market Cap Weighted Average 4.2%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
ENXTPA:ALMED Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (7 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in EUR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
ENXTPA:ALMED Future Estimates Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
ENXTPA:ALMED Past Financials Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income *
2017-12-31 27 -4 -11
2017-09-30 28 -4 -10
2017-06-30 29 -4 -10
2017-03-31 29 -2 -9
2016-12-31 29 -1 -8
2016-09-30 29 1 -5
2016-06-30 29 3 -3
2016-03-31 28 1 -2
2015-12-31 28 0 -2
2015-09-30 27 -1 -2
2015-06-30 26 -1 -2
2015-03-31 25 0 -1

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Medicrea is high growth as no earnings estimate data is available.
  • Unable to determine if Medicrea is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
ENXTPA:ALMED Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (7 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Medicrea Company Filings, last reported 7 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ENXTPA:ALMED Future Estimates Data
Date (Data in EUR Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
ENXTPA:ALMED Past Financials Data
Date (Data in EUR Millions) EPS *
2017-12-31 -0.93
2017-09-30 -0.96
2017-06-30 -0.99
2017-03-31 -0.90
2016-12-31 -0.80
2016-09-30 -0.58
2016-06-30 -0.35
2016-03-31 -0.26
2015-12-31 -0.17
2015-09-30 -0.20
2015-06-30 -0.23
2015-03-31 -0.18

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Medicrea will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine Medicrea's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. Medicrea's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Healthcare companies here
  3. Medicrea's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Medicrea's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the France market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the France market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Medicrea has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

ALMED Past Performance

  How has Medicrea performed over the past 5 years?

  • Medicrea's last earnings update was 227 days ago.
The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Medicrea's growth in the last year to its industry (Medical Equipment).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Medicrea does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Medicrea's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Medicrea's 1-year growth to the Europe Medical Equipment industry average as it is not currently profitable.
Earnings and Revenue History
Medicrea's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Medicrea Company Filings, last reported 7 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ENXTPA:ALMED Past Revenue, Cash Flow and Net Income Data
Date (Data in EUR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2017-12-31 27.15 -10.73 25.70 2.02
2017-09-30 28.19 -10.37 26.34 1.67
2017-06-30 29.23 -10.02 26.98 1.33
2017-03-31 29.30 -8.79 26.54 1.20
2016-12-31 29.38 -7.57 26.10 1.06
2016-09-30 29.08 -5.38 25.16 0.86
2016-06-30 28.79 -3.19 24.21 0.67
2016-03-31 28.28 -2.35 23.27 0.82
2015-12-31 27.76 -1.52 22.33 0.98
2015-09-30 26.96 -1.74 21.55 1.29
2015-06-30 26.16 -1.97 20.78 1.59
2015-03-31 25.18 -1.50 19.62 1.48
2014-12-31 24.20 -1.02 18.47 1.38
2014-09-30 23.51 -0.39 17.41 1.28
2014-06-30 22.83 0.24 16.35 1.18
2014-03-31 22.84 0.35 15.97 1.22
2013-12-31 22.86 0.47 15.58 1.27
2013-09-30 22.30 -0.03 15.46 1.32
2013-06-30 21.74 -0.53 15.35 1.38
2013-03-31 21.21 -0.84 15.27 1.35
2012-12-31 20.68 -1.15 15.20 1.33
2012-09-30 19.79 -2.05 15.04 1.33
2012-06-30 18.89 -2.96 14.89 1.34
2012-03-31 18.97 -2.68 14.74 1.32
2011-12-31 19.06 -2.39 14.58 1.31
2011-09-30 20.15 -1.64 14.85 1.19

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Medicrea has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Medicrea has efficiently used its assets last year compared to the FR Medical Equipment industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Medicrea improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Medicrea's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Medicrea has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

ALMED Health

 How is Medicrea's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Medicrea's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Medicrea is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Medicrea's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Medicrea's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 1.3x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Medicrea Company Filings, last reported 7 months ago.

ENXTPA:ALMED Past Debt and Equity Data
Date (Data in EUR Millions) Total Equity Total Debt Cash & Short Term Investments
2017-12-31 21.79 21.13 11.98
2017-09-30 21.79 21.13 11.98
2017-06-30 21.05 22.23 14.12
2017-03-31 21.05 22.23 14.12
2016-12-31 14.08 21.91 8.06
2016-09-30 14.08 21.91 8.06
2016-06-30 12.57 12.10 1.08
2016-03-31 12.57 12.10 1.08
2015-12-31 15.24 10.43 2.17
2015-09-30 15.24 10.43 2.17
2015-06-30 15.43 11.56 4.25
2015-03-31 15.43 11.56 4.25
2014-12-31 12.62 6.97 1.18
2014-09-30 12.62 6.97 1.18
2014-06-30 13.15 4.04 1.07
2014-03-31 13.15 4.04 1.07
2013-12-31 12.94 3.97 1.84
2013-09-30 12.94 3.97 1.84
2013-06-30 12.95 3.97 1.24
2013-03-31 12.95 3.97 1.24
2012-12-31 12.75 4.27 1.46
2012-09-30 12.75 4.27 1.46
2012-06-30 12.85 3.56 0.80
2012-03-31 12.85 3.56 0.80
2011-12-31 12.51 4.11 1.46
2011-09-30 12.51 4.11 1.46
  • Medicrea's level of debt (97%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (33.5% vs 97% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Medicrea has sufficient cash runway for 1.2 years based on current financial obligations.
  • Medicrea has sufficient cash runway for 1.2 years if financial obligations continue to grow at historical rates of 32.4% each year.
X
Financial health checks
We assess Medicrea's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Medicrea has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

ALMED Dividends

 What is Medicrea's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Medicrea dividends.
If you bought €2,000 of Medicrea shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Medicrea's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Medicrea's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
ENXTPA:ALMED Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Europe Medical Equipment Industry Average Dividend Yield Market Cap Weighted Average of 134 Stocks 1.5%
France Market Average Dividend Yield Market Cap Weighted Average of 362 Stocks 3%
France Minimum Threshold Dividend Yield 10th Percentile 0.9%
France Bottom 25% Dividend Yield 25th Percentile 1.4%
France Top 25% Dividend Yield 75th Percentile 3.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

ENXTPA:ALMED Future Dividends Estimate Data
Date (Data in €) Dividend per Share (annual) Avg. No. Analysts

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Medicrea has not reported any payouts.
  • Unable to verify if Medicrea's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Medicrea's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Medicrea has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Medicrea's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Medicrea afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Medicrea has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

ALMED Management

 What is the CEO of Medicrea's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Denys Sournac, image provided by Google.
Denys Sournac
COMPENSATION €6,000
CEO Bio

Mr. Denys Sournac serves as the Owner, President and Chief Executive Officer at Orsco Laboratoire Vétérinaire, SAS. He also serves as the Chairman of Orsco Laboratoire Vétérinaire, SAS. Mr. Sournac has been a Director at Medicrea since March 29, 2002.

CEO Compensation
  • Denys's compensation has been consistent with company performance over the past year.
  • Denys's compensation appears reasonable for a company of this size and profit level.
Management Team Tenure

Average tenure of the Medicrea management team in years:

0.8
Average Tenure
  • The average tenure for the Medicrea management team is less than 2 years, this suggests a new team.
Management Team

Denys Sournac

TITLE
Co-Founder
COMPENSATION
€6K

Jean Caffiero

TITLE
Co-Founder
COMPENSATION
€6K

Fabrice Kilfiger

TITLE
Chief Financial Officer

Pierre-Laurent Ravis

TITLE
Chief Information Officer

Thomas Mosnier

TITLE
Chief Scientific Officer

Nadège Bourdois

TITLE
Vice President of Human Ressources & Legal

David Ryan

TITLE
Vice President of Product Development & Marketing

Rick Kienzle

TITLE
Chief Commercial & Business Development Officer and Director
TENURE
2 yrs

Joseph Walland

TITLE
Executive Vice President of U.S. Sales
TENURE
0.8 yrs

Rick Washburn

TITLE
Executive Vice President of UNiD™ ASI
TENURE
0.8 yrs
Board of Directors Tenure

Average tenure of the Medicrea board of directors in years:

16.4
Average Tenure
  • The average tenure for the Medicrea board of directors is over 10 years, this suggests they are a seasoned and experienced board.
Board of Directors

Jean Caffiero

TITLE
Co-Founder
COMPENSATION
€6K
TENURE
16.4 yrs

Rick Kienzle

TITLE
Chief Commercial & Business Development Officer and Director
TENURE
2 yrs

Christophe Bonnet

TITLE
Independent Director
COMPENSATION
€4K
TENURE
16.4 yrs

Denys Sournac

TITLE
Co-Founder
COMPENSATION
€6K

M. Ory

TITLE
Independent Director
COMPENSATION
€4K
AGE
59
TENURE
11.2 yrs

Marc Recton

TITLE
Independent Director
COMPENSATION
€4K
TENURE
15.2 yrs

Patrick Bertrand

TITLE
Director
COMPENSATION
€4K
AGE
64
TENURE
16.4 yrs

Jean Moreno

TITLE
Independent Director
COMPENSATION
€4K
TENURE
16.4 yrs

Pierre Burel

TITLE
Director
TENURE
16.4 yrs
Recent Insider Trading
  • No 3 month insider trading information.
Who owns this company?
X
Management checks
We assess Medicrea's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap and profit (greater than 0.5% of the company's profit + 0.03% of market cap)? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Medicrea has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

ALMED News

External News
Loading...
Simply Wall St News

What You Must Know About Medicrea's (EPA:ALMED) Major Investors

In this analysis, my focus will be on developing a perspective on Medicrea’s (EPA:ALMED) latest ownership structure, a less discussed, but important factor. … The impact of a company's ownership structure affects both its short- and long-term performance. … The effect of an active institutional investor with a similar ownership as a passive pension-fund can be vastly different on a company's corporate governance and accountability to shareholders.

Simply Wall St -

How Financially Strong Is Medicrea (EPA:ALMED)?

Medicrea (EPA:ALMED) is a small-cap stock with a market capitalization of €39.20m. … While investors primarily focus on the growth potential and competitive landscape of the small-cap companies, they end up ignoring a key aspect, which could be the biggest threat to its existence: its financial health. … Medical Equipment companies,

Simply Wall St -

With A -41.36% Earnings Drop, Is Medicrea's (EPA:ALMED) A Concern?

After reading Medicrea's (ENXTPA:ALMED) most recent earnings announcement (31 December 2017), I found it useful to look back at how the company has performed in the past and compare this against the latest numbers. … I use data from the most recent 12 months, which annualizes the latest 6-month earnings release, or some times, the latest annual report is already the most recent financial data. … Though Medicrea's past data is helpful, it is only one aspect of my investment thesis.

Simply Wall St -

How Does Medicrea (EPA:ALMED) Affect Your Portfolio Returns?

A popular measure of market risk for a stock is its beta, and the market as a whole represents a beta value of one. … Based on this beta value, ALMED appears to be a stock that an investor with a high-beta portfolio would look for to reduce risk exposure to the market. … However, this is the opposite to what ALMED’s actual beta value suggests, which is lower stock volatility relative to the market.

Simply Wall St -

How Financially Strong Is Medicrea (EPA:ALMED)?

ALMED has built up its total debt levels in the last twelve months, from €10.43M to €21.91M , which comprises of short- and long-term debt. … Moving onto cash from operations, its trivial cash flows from operations make the cash-to-debt ratio less useful to us, though these low levels of cash means that operational efficiency is worth a look. … Since total debt levels have outpaced equities, ALMED is a highly leveraged company.

Simply Wall St -

ALMED Company Info

Map
Description

Medicrea designs, manufactures, and distributes implants in France. It offers PASS range, a polyaxial spine system; PASS LP, a thoraco-lumbar fixation system; LigaPASS, a band connector for posterior thoracic fixation; and PASS ANT, a polyaxial low profile thoraco-lumbar system for anterior approach. The company also provides a range of implants for the cervical spine, including C-JAWS, an anterior cervical spinal fixation system; IMPIX C, a sterile PEEK optima cervical inter body device; Impix C+, a sterile PEEK optima cervical inter body device that is prefilled with bone substitute; and IMPIX-MANTA, a sterile PEEK optima cervical inter body device, which is preassembled on holder and delivers with disposable instrumentation kit. Its implants for cervical spine also include IMPIX-MANTA +, a sterile PEEK optima cervical inter body device, which is prefilled with bone substitutes, as well as preassembled on disposable holder/impactor and delivered with disposable instrumentation kit; and GRANVIA C, a MRI compatible ceramic cervical disc. In addition, the company offers implants and bone substitutes for the thoracic and lumbar spine, such as IMPIX-L, a sterile PEEK optima lumbar inter body device for posterior approach; IMPIX-TLIF, a sterile PEEK optima lumbar inter body device for transformational approach; IMPIX ALIF, a sterile PEEK optima lumbar inter body device for anterior approach; STABOLT, a lumbosacral anterior plating system; OSMOSYS, a macro porous bone substitute; IMPIX-DLIF and IMPIX-DLIF SLIM sterile PEEK optima lumbar interbody devices for direct or oblique lateral approach; and IMPIX-S, an oblique TLIF interbody device. Its implants are designed to treat scoliosis, degenerative deformation, trauma, and tumors; and are used in various traditional and advanced surgical techniques, such as minimally-invasive surgery. The company was founded in 1990 and is based in Rillieux-la-Pape, France.

Details
Name: Medicrea
ALMED
Exchange: ENXTPA
Founded: 1990
€44,567,349
16,206,309
Website: http://www.medicrea.com
Address: Medicrea
5389 route de Strasbourg,
Rillieux-la-Pape,
Rhône-Alpes, 69140,
France
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ENXTPA ALMED Ordinary Shares Euronext Paris FR EUR 29. Jun 2006
OTCPK MRNT.F Ordinary Shares Pink Sheets LLC US USD 29. Jun 2006
OTCPK MRNT.Y SPONSORED ADS Pink Sheets LLC US USD 09. Aug 2018
Number of employees
Current staff
Staff numbers
169
Medicrea employees.
Industry
Healthcare Equipment
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2018/08/15 18:15
End of day share price update: 2018/08/15 00:00
Last estimates confirmation: 2017/04/28
Last earnings update: 2017/12/31
Last annual earnings update: 2017/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.